EUCTR2016-004750-15-DE进行中（未招募）1 期
A randomized phase II study of Durvalumab (MEDI4736) and Tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma. - MEDISARC
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
- •2. Age = 18 years at time of study entry
- •3. Body weight > 30kg at study inclusion
- •4. Histologically confirmed diagnosis of metastatic or advanced soft tissue sarcoma of intermediate or high grade [according to FNCLCC score; intermediate=grade 2 score of 4-5 points, high grade = grade 3 score of 6-8 points] with disease progression within 6 months prior to study inclusion:
- •Fibrosarcoma
- •Pleomorphic high grade sarcoma (malignant fibrous histiocytoma”)
- •Leiomyosarcoma
- •Liposarcoma (myxoid liposarcoma, dedifferentiated liposarcoma, pleomorphic liposarcoma)
- •Malignant glomus tumor
- •Rhabdomyosarcoma, alveolar or pleomorphic (excluding embryonal)
- •Vascular sarcoma (angiosarcoma)
- •Synovial sarcoma
- •High-grade sarcoma, not otherwise specified (NOS)
- •Malignant peripheral nerve sheath tumors
- •Other types of sarcoma (not listed as ineligible), if approved by the coordinating investigator/study coordinator.
- •Uncertain differentiation (epithelioid, alveolar soft part, clear cell, desmoplastic small round cell, malignant mesenchymoma, PEComa), chondrosarcoma, Ewing sarcomas/PNET, chordoma, malignant solitary fibrous tumors, embryonal rhabdomyosarcoma, osteosarcoma, gastrointestinal stromal tumors, dermatofibrosarcoma protuberans, inflammatory myofibroblastic sarcoma (low-grade), neuroblastoma, malignant mesothelioma, and mixed mesodermal tumors of the uterus
- •(Study inclusion is based on local histopathological diagnosis).
- •5. Metastatic or locally advanced STS, not amendable to surgery with curative intention.
- •6. No prior treatment line for advanced or metastatic disease.
- •7. ECOG performance status 0-2
- •8. Patients with measurable disease (at least one uni-dimensionally measurable target lesion by CT-scan or MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) are eligible.
- •9. If prior palliative radiotherapy has been given to metastatic lesions: either =1 measurable lesion remains outside the radition field or the sole lesion meets RECIST 1.1 criteria for progression at study entry.
- •10. Patients with bone lesions as the only measurable lesion are eligible, provided that lesions consist of soft tissue, which is measurable via CT or MRI.
- •11. Prior radiotherapy and surgery are allowed if completed 4 weeks (for minor surgery and palliative radiotherapy for bone pain: 2 weeks) prior to start of treatment and patient recovered from toxic effects.
- •12. Adequate blood count, liver-enzymes, and renal function:
- •Haemoglobin = 9.0 g/dL
- •Absolute neutrophil count (ANC) = 1.5 x 10^9/L (> 1500 per mm³)
- •Platelet count = 100 x 10^9/L (>100,000 per mm³)
- •Serum bilirubin = 1.5 x ULN. This will not apply to subjects with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.
- •AST (SGOT)/ALT (SGPT) = 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be = 5x ULN
- •Serum creatinine CL>40 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine clearance
- •Males: Creatinine CL (mL/min) = Weight (kg) x (140 – Age)/ (72 x serum creatinine (mg/dL))
排除标准
- •1. Patients who are suitable for anthracycline-based combination therapies
- •2. Cardiac events such as arrhythmias, myocardial infarction, CHF, apoplexy, lung embolism within 6 months prior to study treatment
- •3. Mean QT interval corrected for heart rate (QTc) =470 ms calculated from 3 electrocardiograms (ECGs) using Fredericia’s correction
- •4. Uncontrolled severe hypertension (failure of diastolic blood pressure to fall below 100 mmHg and systolic blood pressure>160 mmHg)
- •5. Previous malignancy (other than STS) which either progresses or requires active treatment
- •Exceptions are: basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a or T1b prostate carcinoma, or superficial bladder tumor [Ta, Tis and T1]
- •6. History or clinical evidence of CNS metastases
- •Exceptions are: Subjects who have completed local therapy and who meet both of the following criteria:
- •a) are asymptomatic and
- •b) have no requirement for steroids 6 weeks prior to start of study treament. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS metastases
- •7. Active or prior documented autoimmune disease within the past 2 years NOTE: Subjects with vitiligo, Grave’s disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded
- •8. Active or prior documented inflammatory bowel disease (e.g. Crohn’s disease, ulcerative colitis)
- •9. History of primary immunodeficiency
- •10. History of allogeneic organ transplant
- •11. History of hypersensitivity to durvalumab, tremelimumab (alone or in combination), doxorubicin or any of the constituents of the products
- •12. Medication that is known to interfere with any of the agents applied in the trial
- •13. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus, or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
- •14. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study medication Note: Local surgery of isolated lesions for palliative intent is acceptable
- •15. Any unresolved toxicity >CTCAE grade 2 from previous anti-cancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
- •Patients with Grade=2 neuropathy will be evaluated on a case-by-case basis after consultation with the Coordinating Investigator
- •Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab (if applicable) may be included only after consultation with the Coordinating Investigator
- •16. Any prior Grade=3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE>Grade 1
- •17. Known history of previous clinical diagnosis of tuberculosis
- •18. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
- •19. Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method o
研究者
相似试验
进行中（未招募）
1 期
Treatment of patients with HIV-1 and advanced solid tumors with Durvalumabadvanced solid tumors in HIV-1 infected patientsEUCTR2016-004524-38-ESSpanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón)20
招募中
1 期
Durvalumab (immunotherapy) maintenance after thoracic chemoradiotherapy (CRT) in frail small cell lung cancer patients whose disease is limited to the thoraxCTIS2024-512224-11-00nicancer110
进行中（未招募）
2 期
A Phase II study of Durvalumab (MEDI4736) plus carboplatin and etoposide in elderly patients with extensive-stage small-cell lung cancerextensive-stage small cell lung cancerJPRN-jRCTs071210050Koichi Azuma40
招募中
不适用
Phase II, single-arm study of durvalumab (MEDI4736) and AZD 6738 combination therapy in relapsed small cell lung cancer SubjectsKCT0005058Samsung Medical Center45
招募中
2 期
Combined radiotherapy and immunotherapy for men with early metastatic prostate cancer not on hormone therapyProstate CancerACTRN12619000097145orthern Sydney Local Health District30